| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 08/27/2008 | CN100413850C Chemical compounds |
| 08/27/2008 | CN100413538C Remedy for corneal failure |
| 08/27/2008 | CN100413508C Process for preparing water soluble phosphonooxymethyl derivatives of alcohol and phenol |
| 08/27/2008 | CN100413496C The use of sussinate derivative esters for the treatment of dementia |
| 08/26/2008 | US7417064 3-aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake |
| 08/26/2008 | US7417058 Reacting cyanophenyl-4-sulfonylchloride with a piperidine-4-oxo in presence of ethylene glycol to form an intermediate, reducing cyano group, followed by amidation, then reacting with an amine to form sulfonamide end |
| 08/26/2008 | US7417050 Cognition activators; Alzheimer's disease; attention deficit disorders; Parkinson's disease; Huntington's disease; neurodegenerative disease |
| 08/26/2008 | US7417049 Furyl compounds |
| 08/26/2008 | US7417043 3-substituted 4-(phenyl-N-alkyl)-piperazine derivatives; central nervous system disorders; dualistic dopaminergic action profile with antagonist-like effects on brain neurochemistry and mild agonist-like effects on normal behavior, induce inhibition of behavior in hyperactivity; oral bioavailability |
| 08/26/2008 | US7417035 Phospholipid derivatives of non-steroidal anti-inflammatory drugs |
| 08/26/2008 | US7417034 Pharmaceutically active uridine esters |
| 08/26/2008 | US7417029 Using an interleukin-1 beta converting enzyme inhibitor pro-drug to treat apoptosis-, interferon-gamma inducing factor or interferon-gamma inducing diseases; antiinflammatory and -proliferative agents; autoimmune/degenerative disesesdiseases |
| 08/26/2008 | US7416885 Proliferation factor is obtained from the UCHT1 rat thyroid cell line, or a fragment, analogue or derivateve |
| 08/26/2008 | US7416848 DNA encoding SNORF25 receptor |
| 08/26/2008 | US7416839 Immunoassay; for therapeutic treatment of Bovine spongiform encephalopathy (BSE) in cows, Scrapie disease in sheep and Creutzfeldt-Jacob syndrome in humans |
| 08/26/2008 | US7416730 Derivatives of the IL-2 receptor gamma chain, their production and use |
| 08/26/2008 | CA2432129C Pyrazole compounds useful as protein kinase inhibitors |
| 08/26/2008 | CA2361614C Compositions for treating inflammatory response |
| 08/26/2008 | CA2347474C Bicyclic nitrogen heterocycles |
| 08/26/2008 | CA2343880C Polyketide synthase enzymes and recombinant dna constructs therefor |
| 08/26/2008 | CA2330681C Control of pain with endogenous cannabinoids |
| 08/26/2008 | CA2292638C Composition comprising ketanserin and l-carnitine or an alkanoyl l-carnitine for the treatment of crps |
| 08/26/2008 | CA2274825C Substituted nitrogen containing heterocycles as inhibitors of p38 protein kinase |
| 08/26/2008 | CA2239780C A process for regulating vagal tone |
| 08/26/2008 | CA2208981C Novel trienoic retinoid compounds and methods |
| 08/21/2008 | WO2008101247A2 6 ' substituted indole and indazole derivatives having 5-ht6 receptor affinity |
| 08/21/2008 | WO2008101202A1 N-17-alkylated prodrugs of opioids |
| 08/21/2008 | WO2008101139A1 Sustained-release tablet formulations of piperazine-piperidine antagonists and agonists of the 5-ht1a receptor having enhanced intestinal dissolution |
| 08/21/2008 | WO2008101098A2 Use of botulinum toxin and enzymes for treating bladder or prostata disorders, or hyperhydrosis |
| 08/21/2008 | WO2008101012A1 Use of ranolazine for the treatment of non-coronary microvascular diseases |
| 08/21/2008 | WO2008100715A1 Aza-isoindolones and their use as metabotropic glutamate receptor potentiators - 613 |
| 08/21/2008 | WO2008100628A2 Glutathione peroxidase mimetics for treatment of neurodegenerative, pulmonary and inflammatory diseases |
| 08/21/2008 | WO2008100560A2 Estrogen receptor modulators, associated pharmaceutical compositions and methods of use |
| 08/21/2008 | WO2008100463A1 3,4-dihydr0-l,4-benz0xazine, 3, 4-dihydr0-1, 4-benzothiazine and 1,2,3,4-tetrahydro-quinoxaline derivatives as alpha2c adrenoreceptor agonists |
| 08/21/2008 | WO2008100459A1 Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists |
| 08/21/2008 | WO2008100450A2 Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury |
| 08/21/2008 | WO2008099928A1 Placental protein having action of regulating protease activity and its related gene |
| 08/21/2008 | WO2008099924A1 Chlorella having active oxygen scavenging ability |
| 08/21/2008 | WO2008099912A1 5ht4 receptor antagonist |
| 08/21/2008 | WO2008099781A1 Therapeutic or prophylactic agent for demyelinating disease comprising amino alcohol derivative as active ingredient |
| 08/21/2008 | WO2008099469A1 Composition and method for suppressing lipid peroxidation in erythrocytes |
| 08/21/2008 | WO2008099426A1 A composition for selective serotonin reuptake inhibition and process thereof |
| 08/21/2008 | WO2008099210A2 Piperazine derivatives for treatment of ad and related conditions |
| 08/21/2008 | WO2008099175A1 Camp dependent induction of autophagy |
| 08/21/2008 | WO2008099083A2 Use of neuroprotective compounds for obtaining drugs for treating neurodegenerative diseases |
| 08/21/2008 | WO2008099082A1 New aminopyrrolo[1,2-α]indole et aminopyridazino[1,6-α]indole derivatives, method for preparing the same and pharmaceutical compositions containing the same |
| 08/21/2008 | WO2008098978A2 Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor |
| 08/21/2008 | WO2008098960A1 Process for preparing entacapone substantially free of z-isomer, synthesis intermediates thereof and a new crystalline form |
| 08/21/2008 | WO2008098892A1 Fast dissociating dopamine 2 receptor antagonists |
| 08/21/2008 | WO2008098857A1 2-aminooxazolines as taar1 ligands |
| 08/21/2008 | WO2008098751A1 New compounds with antiglutamatergic properties and uses thereof |
| 08/21/2008 | WO2008098371A1 Compositions and method for reducing amyloid beta in a mammal |
| 08/21/2008 | WO2008070000A3 Treatment of anxiety with eszopiclone |
| 08/21/2008 | WO2008068614A3 Stereoselective synthesis of 1-[6-ethyl-1,2-dihydroxy-propyl)-pyridin-3-yl]-3-[2-(4-methyl-piperazin-1-yl)-benzyl]-pyrrolidin-2-one |
| 08/21/2008 | WO2008052766A3 Cationic colloidal carriers for delivery of active agents to the blood-brain barrier in the course of neuroinflammatory diseases |
| 08/21/2008 | WO2007144196A3 Peptide compounds for treating refractory status epilepticus |
| 08/21/2008 | WO2007020261A3 Selected cgrp antagonists, methods for the production thereof and their use as medicaments |
| 08/21/2008 | US20080201789 Variants and exons of the glyt1 transporter |
| 08/21/2008 | US20080200674 Anticoagulants; cardiovascular disorders; atherosclerosis; antiarthritic agents;Alzheimer's disease; anticancer agents |
| 08/21/2008 | US20080200567 In vivo screening models for treatment of alzheimer's disease and other qpct-related disorders |
| 08/21/2008 | US20080200557 N-substituted dopamine derivatives; septic shock, microbial infection, carcinogenesis, a mutation, Parkinson's or Alzheimer's disease, toxic effects of chemotherapy or radiation therapy; N-acetyldopamine; 3-methoxy dopamine |
| 08/21/2008 | US20080200556 Amine Compounds And Inhibiting Neurotrasmitter Reuptake |
| 08/21/2008 | US20080200555 Use of norepinephrine reuptake inhibitors for the treatment of tic disorders |
| 08/21/2008 | US20080200551 Flourene Derivative |
| 08/21/2008 | US20080200547 Highly Purified Ethyl EPA and Other EPA Derivatives |
| 08/21/2008 | US20080200541 Central nervous system disorders; schizophrenia; serotonine receptor antagonist; side effect reduction |
| 08/21/2008 | US20080200530 compound is a selective 5-HT2A inverse agonist or inhibits JC virus infection of human glial cells in patients with carcinomas, lymphoproliferative disorder, HIV, AIDS, immunosupressive therapy; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(4-fluoro-phenyl)-urea; pyrazole, urea or thiourea |
| 08/21/2008 | US20080200529 Novel 2-Amino Benzimidazole Derivatives and Their Use As Modulators Of Small-Conductance Calcium-Activated Potassium Channels |
| 08/21/2008 | US20080200524 Treating pain, inflammation and traumatic injury; using 2-pyridinyl-phenyl-4-amido-p-sulfono or sulfonamidobenzene derivatives |
| 08/21/2008 | US20080200520 Iron Modulators |
| 08/21/2008 | US20080200514 Neurodegeneration, cancer, rheumatoid disordes, kidney diseases, diabetes; such as dabigatran etexilate |
| 08/21/2008 | US20080200509 Utilizing such as 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide against cancer growth |
| 08/21/2008 | US20080200508 Controlled extended release of serotonin receptor anatagonist; alleviating sleep apnea; kits |
| 08/21/2008 | US20080200504 non-peptide NK-3 receptor ligands; anxiety, depression, schizophrenia, obesity; 2-Phenyl-quinoline-4-carboxylic acid (1-pyridin-4-yl-propyl) amide; reacting the 2-phenyl-quinolinyl-4-carbonyl chloride with a pyridylalkylamine to form the amide |
| 08/21/2008 | US20080200500 Quinoline Derivatives as Nk3 Antagonists |
| 08/21/2008 | US20080200496 SUBSTITUTED 1H-PYRROLO[3,2-b, 3,2-c, and 2,3-c]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE Ie |
| 08/21/2008 | US20080200495 Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof |
| 08/21/2008 | US20080200494 Imidazopyridine Derivatives |
| 08/21/2008 | US20080200493 Use of Oxycodone for Treating Visceral Pain |
| 08/21/2008 | US20080200492 Methods for the treatment of alcohol abuse, addiction and dependency |
| 08/21/2008 | US20080200491 1,2-Dihydro-Spiro[3H-Indole-3,4'-Piperidine] Compounds, as Modulators of the Mas Receptor Novel |
| 08/21/2008 | US20080200479 Acid moiety selected from pyroglutamic acid, N-(2-carboxyphenyl)-glycine acid, diglycolic acid, orotic acid, galactaric acid, nicotinic acid, hippuric acid; treatment of nervous system disorders such as schizophrenia, obsessive compulsive disorder, bipolar depression, anxiety, mania, Tourette syndrome |
| 08/21/2008 | US20080200473 GABA a receptor; hypnotic agents with a lower risk of side effects; sleep, sedative, muscle relaxant; 4-Dimethylamino-N-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-benzamide |
| 08/21/2008 | US20080200472 urinary incontinence, ulcer, inflammatory bowel disease, addiction, Parkinson's, anxiety, epilepsy, seizures, pruritus, psychosis, cognitive disorder, Huntington's chorea, ALS, retinopathy, migraine, vomiting, dyskinesia, depression; Pyridazinylpiperazine compounds; VR1 Vanilloid Receptor 1 antagonists |
| 08/21/2008 | US20080200471 central nervous system disorders; mood or cognitive disorder; gastrointestinal disorders; 4-methyl-7-[(6-piperazin-1-yl-1H-indol-1-yl)sulfonyl]-3,4-dihydro-2H-1,4-benzoxazine; 1-methyl-5-[(6-piperazin-1-yl-1H-indol-1-yl)sulfonyl]-1H-indole; 6-(6-Piperazin-1-yl-indole-1-sulfonyl)-4H-benzo[1,4]oxazin-3-one |
| 08/21/2008 | US20080200470 serotonin 5-HT1A receptor agonists; N-heterocyclclediones substituted with a chroman-2-yl, 2-quinolyl, or phenoxy group; 2-[4-[(Chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydroimidazo[1,5-a]pyridine; Parkinson's, cerebral damage by thromboembolitic ictus, depression, migraine, psychosis, urinary disorde |
| 08/21/2008 | US20080200463 N-[5-(5-formyl-2-thienyl)-4-methyl-1,3-thiazol-2-yl]acetamide; autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer |
| 08/21/2008 | US20080200455 1-Aryl- or 1-Alkylsulfonyl-Heterocyclylbenzazoles As 5-Hydroxytryptamine-6 Ligands |
| 08/21/2008 | US20080200454 Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| 08/21/2008 | US20080200452 Oral, Rapidly Disintegrating Film, Which Cannot be Spat Out, for a Neuroleptic |
| 08/21/2008 | US20080200447 Neurotherapeutic Compositions and Method |
| 08/21/2008 | US20080200445 Heterocyclic aspartyl protease inhibitors |
| 08/21/2008 | US20080200443 Zinc complexes of natural amino acids for treating elevated copper caused toxicities |
| 08/21/2008 | US20080200441 Estrogen receptor modulators associated pharmaceutical compositions and methods of use |
| 08/21/2008 | US20080200438 such as multiple sclerosis, neuritis, amylotrophic lateral sclerosis; use of aminoalcohols or phosphate derivatives thereof, such as 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl-propane-1,3-diol or phosphoric acid mono-2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl-propyl]ester |
| 08/21/2008 | US20080200420 Engineered RNA precursors encoded in plasmids and/or other vectors; simple, low cost technique utilizing DNA molecule production; host cells, transgenes |
| 08/21/2008 | US20080200407 Suppress the immunoreactivity of a CpG motif and preventing and treating immune-mediated diseases such as arthritis |
| 08/21/2008 | US20080200399 Taurine, cysteic acid residue and residue of a protease or calpain inhibitor; directly, indirectly bonded to each other;leucyl argininal residues in form of aldehyde; effective to inhibit calpains; acetal prodrug residues can be converted to the aldehyde form before, during, or after administration |
| 08/21/2008 | US20080200398 Compounds For Enzyme Inhibition |
| 08/21/2008 | US20080200397 dextrorotatory amino acids; vGek with Dval-gly-Dglu-Dlys as a central D-amino acid sequence; protect against amyloid-mediated neurotoxicity; have no similarities to the amino acid sequence in beta -amyloid regardless of the direction in which they are read |